Assessing a drug compound by its activity, not simply its structure, is a new approach that could speed the search for COVID-19 therapies and reveal more potential therapies for other diseases. This ...
Honghui Hu of Wanhuida Intellectual Property considers the impact of the structure-activity relationship on the inventiveness assessment of pharmaceutical compounds Bayer Intellectual Property GmbH ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback